Helen Howard

876 total citations
24 papers, 438 citations indexed

About

Helen Howard is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Helen Howard has authored 24 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Helen Howard's work include Renal cell carcinoma treatment (7 papers), Cancer Treatment and Pharmacology (5 papers) and Breast Cancer Treatment Studies (5 papers). Helen Howard is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Cancer Treatment and Pharmacology (5 papers) and Breast Cancer Treatment Studies (5 papers). Helen Howard collaborates with scholars based in United Kingdom, United States and Singapore. Helen Howard's co-authors include Stuart Hawtin, Mark Wheatley, Helen Marshall, Julia Brown, Fiona Collinson, Christopher McCabe, Carly S. Rivers, Sue Pavitt, P J Guillou and David Jayne and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Biochemistry.

In The Last Decade

Helen Howard

24 papers receiving 430 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Helen Howard United Kingdom	12	274	186	95	86	84	24	438
Flora Yan United States	13	159 0.6×	81 0.4×	159 1.7×	83 1.0×	9 0.1×	28	426
Koichiro Ishida Japan	13	126 0.5×	195 1.0×	191 2.0×	112 1.3×	8 0.1×	23	483
Makoto Nakiri Japan	10	145 0.5×	52 0.3×	149 1.6×	67 0.8×	12 0.1×	51	308
Chandler S. Cortina United States	10	106 0.4×	86 0.5×	34 0.4×	15 0.2×	79 0.9×	70	313
Giovanni Vicario Italy	10	121 0.4×	29 0.2×	166 1.7×	27 0.3×	16 0.2×	48	358
Julio Sánchez de Cos Spain	11	154 0.6×	51 0.3×	300 3.2×	81 0.9×	4 0.0×	14	489
Satoshi Hokari Japan	10	78 0.3×	21 0.1×	60 0.6×	109 1.3×	4 0.0×	22	288
Ziyang Huang China	9	53 0.2×	31 0.2×	49 0.5×	75 0.9×	3 0.0×	36	295
Jinfeng Zhan China	10	26 0.1×	74 0.4×	53 0.6×	92 1.1×	9 0.1×	21	322
Hans‐Jörg Weig Germany	12	19 0.1×	54 0.3×	30 0.3×	217 2.5×	11 0.1×	17	485

Countries citing papers authored by Helen Howard

Since Specialization

Citations

This map shows the geographic impact of Helen Howard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Howard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Howard more than expected).

Fields of papers citing papers by Helen Howard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Howard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Howard. The network helps show where Helen Howard may publish in the future.

Co-authorship network of co-authors of Helen Howard

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Howard. A scholar is included among the top collaborators of Helen Howard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Howard. Helen Howard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Zarkar, Anjali, et al.. (2023). First UK patient cohort treated with stereotactic ablative radiotherapy for primary kidney cancer. SHILAP Revista de lepidopterología. 4(4). 464–472. 4 indexed citations

2.

Vasudev, Naveen, Sarah Brown, Tom Waddell, et al.. (2021). LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM). Annals of Oncology. 32. S1304–S1305. 4 indexed citations

3.

Corrie, Pippa, Helen Marshall, Ruth Plummer, et al.. (2021). The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer. 21(1). 761–761. 18 indexed citations

4.

Brown, Judy, Christy Ralph, David Meads, et al.. (2021). LBA28 STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC). Annals of Oncology. 32. S1303–S1304. 2 indexed citations

5.

Wadsley, Jonathan, Nicholas S. Reed, Olusola Olusesan Faluyi, et al.. (2020). NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open. 10(2). e034527–e034527. 13 indexed citations

6.

Buckley, Hannah, Fiona Collinson, Louise Flanagan, et al.. (2019). PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. BMC Cancer. 19(1). 1102–1102. 13 indexed citations

7.

Swinson, Daniel, Mohan Hingorani, Jo Dent, et al.. (2019). Best supportive care (BSC) with or without low-dose chemotherapy (chemo) in frail elderly patients with advanced gastroesophageal cancer (aGOAC): The uncertain randomization of the GO2 phase III trial.. Journal of Clinical Oncology. 37(15_suppl). 4051–4051. 5 indexed citations

8.

Hall, Peter, Simon Lord, Michelle Collinson, et al.. (2017). A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO). British Journal of Cancer. 116(4). 472–478. 27 indexed citations

9.

Boon, C.S., M. Tiffany, Tom Roques, et al.. (2016). UK Contouring Variation in Nasopharyngeal Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 96(2). E393–E393. 4 indexed citations

10.

Collinson, Fiona, Walter M. Gregory, Christopher McCabe, et al.. (2012). The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic Renal Cancer. BMC Cancer. 12(1). 598–598. 23 indexed citations

11.

Hall, Peter, Simon Lord, Michelle Collinson, et al.. (2012). Three, two, or one drug chemotherapy for frail or elderly patients with advanced gastroesophageal cancer (321GO): A feasibility study.. Journal of Clinical Oncology. 30(4_suppl). 97–97. 1 indexed citations

12.

Collinson, Fiona, David Jayne, Alessio Pigazzi, et al.. (2011). An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer. International Journal of Colorectal Disease. 27(2). 233–241. 182 indexed citations

13.

Collinson, Fiona, Janet E. Brown, Christopher McCabe, et al.. (2011). The STAR trial: can quality of life benefit offset any survival detriment?. Trials. 12(S1). 1 indexed citations

14.

Poole, C. J., Louise Hiller, Helen Howard, et al.. (2008). tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC). Journal of Clinical Oncology. 26(15_suppl). 506–506. 27 indexed citations

15.

Wardley, Andrew, Louise Hiller, Helen Howard, et al.. (2008). tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation. British Journal of Cancer. 99(4). 597–603. 14 indexed citations

16.

Poole, C. J., Louise Hiller, Helen Howard, et al.. (2006). Tolerability of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy in the randomized phase III tAnGo trial for invasive higher risk early stage breast cancer.. Breast Cancer Research and Treatment. 100. 1 indexed citations

17.

Poole, Christopher, Helen Howard, Louise Hiller, et al.. (2004). A prospective evaluation of pulmonary, cardiac, and hepatic function (fn) in ‘tAnGo’: A randomized phase III trial of gemcitabine (G) in paclitaxel (T)-containing, epirubicin/cyclophosphamide (EC)-based, adjuvant chemotherapy (CT) for early stage breast cancer. Journal of Clinical Oncology. 22(14_suppl). 821–821. 1 indexed citations

18.

Poole, Christopher, Helen Howard, Louise Hiller, et al.. (2004). A prospective evaluation of pulmonary, cardiac, and hepatic function (fn) in ‘tAnGo’: A randomized phase III trial of gemcitabine (G) in paclitaxel (T)-containing, epirubicin/cyclophosphamide (EC)-based, adjuvant chemotherapy (CT) for early stage breast cancer. Journal of Clinical Oncology. 22(14_suppl). 821–821. 1 indexed citations

19.

Wheatley, Mark, Stuart Hawtin, Helen Howard, et al.. (2003). Agonist binding to peptide hormone receptors. Biochemical Society Transactions. 31(1). 35–39. 12 indexed citations

20.

Hawtin, Stuart, et al.. (2002). Agonist-Specific, High-Affinity Binding Epitopes Are Contributed by an Arginine in the N-Terminus of the Human Oxytocin Receptor. Biochemistry. 41(16). 5086–5092. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact